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Background and Purpose—We investigated whether procedural stroke or death risk of carotid artery stenting (CAS) 
compared with carotid endarterectomy (CEA) is different in patients with and without history of coronary heart disease 
(CHD) and whether the treatment-specific impact of age differs.
Methods—We combined individual patient data of 4754 patients with symptomatic carotid stenosis from 4 randomized trials 
(EVA-3S [Endarterectomy Versus Angioplasty in Patients With Symptomatic Severe Carotid Stenosis], SPACE [Stent-
Protected Angioplasty Versus Carotid Endarterectomy], ICSS [International Carotid Stenting Study], and CREST [Carotid 
Revascularization Endarterectomy Versus Stenting Trial]). Procedural risk was defined as any stroke or death ≤30 days after 
treatment. We compared procedural risk between both treatments with Cox regression analysis, stratified by history of CHD 
and age (<70, 70–74, ≥75 years). History of CHD included myocardial infarction, angina, or coronary revascularization.
Results—One thousand two hundred ninety-three (28%) patients had history of CHD. Procedural stroke or death risk was 
higher in patients with history of CHD. Procedural risk in patients treated with CAS compared with CEA was consistent in 
patients with history of CHD (8.3% versus 4.6%; hazard ratio [HR], 1.96; 95% CI, 0.67–5.73) and in those without (6.9% 
versus 3.6%; HR, 1.93; 95% CI, 1.40–2.65; Pinteraction=0.89). In patients with history of CHD, procedural risk was significantly 
higher after CAS compared with CEA in patients aged ≥75 (CAS-to-CEA HR, 2.78; 95% CI, 1.32–5.85), but not in patients 
aged <70 (HR, 1.71; 95% CI, 0.79–3.71) and 70 to 74 years (HR, 1.09; 95% CI, 0.45–2.65). In contrast, in patients without 
history of CHD, procedural risk after CAS was higher in patients aged 70 to 74 (HR, 3.62; 95% CI, 1.80–7.29) and ≥75 years 
(HR, 2.64; 95% CI, 1.52–4.59), but equal in patients aged <70 years (HR, 1.05; 95% CI, 0.63–1.73; 3-way Pinteraction=0.09).
Conclusions—History of CHD does not modify procedural stroke or death risk of CAS compared with CEA. CAS 
might be as safe as CEA in patients with history of CHD aged <75 years, whereas for patients without history of 
CHD, risk after CAS compared with CEA was only equal in those aged <70 years.   (Stroke. 2019;50:00-00. DOI: 
10.1161/STROKEAHA.118.023085.)
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About 10% to 15% of ischemic strokes are caused by ather-osclerotic stenosis of the internal carotid artery.1 Carotid 
endarterectomy (CEA) and carotid artery stenting (CAS) both 
reduce the long-term risk of ipsilateral stroke in patients with 
symptomatic internal carotid artery stenosis, but the 30-day 
stroke or death risk is higher after CAS than after CEA.2
To improve the balance between risk and benefit of treat-
ment, it is important to identify patient characteristics that 
are associated with higher periprocedural risks of CAS or 
CEA. The risk of CAS depends strongly on age, with increas-
ing periprocedural risk at older ages for patients assigned to 
CAS and the absence of an effect of age on risk for patients 
assigned to CEA.3 Furthermore, clinicians may prefer CAS 
instead of CEA in patients with a history of coronary heart 
disease (CHD) because the periprocedural risk of myocardial 
infarction (MI) is lower after CAS compared with CEA in ran-
domized trials.2 A recent meta-analysis showed that history of 
CHD increased 30-day risk of MI in patients who underwent 
CEA, but not in those who underwent CAS.4 Another study 
showed a trend toward increased periprocedural stroke or 
death risk of CAS compared with CEA in patients without his-
tory of CHD, but more similar risks in the 2 treatment groups 
in patients with history of CHD.5
The influence of age on procedural risks in patients with 
history of CHD is unknown. Therefore, we studied the asso-
ciation between age and procedural risk stratified by history 
of CHD. We hypothesized that if CAS is as safe as CEA in 
patients with history of CHD, the previously reported age 
cutoff of ≥70 years at which CEA is clearly superior to CAS3 
might shift to a higher age in patients with history of CHD.
Methods
Study Population and Design
We used individual patient data from 4 trials that randomly assigned 
patients with symptomatic carotid stenosis to undergo CAS or CEA 
and that are pooled by the Carotid Stenosis Trialists’ Collaboration: 
the EVA-3S trial (Endarterectomy Versus Angioplasty in Patients 
With Symptomatic Severe Carotid Stenosis),6 the SPACE trial (Stent-
Protected Angioplasty Versus Carotid Endarterectomy),7 the ICSS 
(International Carotid Stenting Study),8 and the CREST (Carotid 
Revascularization Endarterectomy Versus Stenting Trial).9 In total, 
these 4 trials included 4754 patients with symptomatic moderate to 
severe internal carotid artery stenosis (≥50% lumen narrowing on 
imaging according to the NASCET [North American Symptomatic 
Carotid Endarterectomy Trial] method10). Detailed methods were 
described previously.6–9 Requests for anonymized pooled data will be 
considered by the Carotid Stenosis Trialists’ Collaboration Steering 
Committee (Leo.Bonati@usb.ch).
For the purposes of this post hoc subgroup analysis, we used 
trial-specific definitions of history of CHD (Table I in the online-only 
Data Supplement). History of CHD included any of the following: 
CHD (not further specified), MI, angina, or any type of coronary 
revascularization.
Outcome Measures
The primary outcome measure was any stroke or death during the 
procedural period (within 30 days after the procedure). The sec-
ondary outcome measure was any stroke, MI, or death during the pro-
cedural period.
Stroke was defined as the occurrence of acute symptoms of focal 
neurological dysfunction that lasted >24 hours and resulted from in-
tracranial vascular disturbance (ischemic or hemorrhagic). Diagnosis 
of MI required presence of at least 2 of 3 criteria: history of typ-
ical chest pain, development of specific abnormalities on an ECG, or 
rise of specific cardiac enzyme levels. MI was not a prespecified end 
point in SPACE; nevertheless, adverse event reports from this trial 
were adjudicated post hoc using the criteria for MI stated above. In 
CREST, MI was diagnosed only if patients had elevated cardiac en-
zyme levels and either history of typical chest pain or specific abnor-
malities on an ECG. Because of the different definition in CREST, 
we did not include MI in the primary outcome measure and analyzed 
the secondary outcome measure in patients from EVA-3S, SPACE, 
and ICSS only.
Statistical Analysis
The primary analysis for the primary and secondary outcome meas-
ures was on a per-protocol (PP) basis including patients who received 
their randomly allocated treatment and who did not suffer a stroke 
before the procedure. Analysis was based on the first occurrence of 
a primary outcome event within 30 days after the procedure. Cox 
proportional hazards analysis was performed to estimate hazard 
ratios (HRs) and 95% CIs adjusted for trial. The proportional haz-
ards assumption was evaluated visually with log-minus-log plots. 
Potential effect modification by history of CHD was analyzed by in-
cluding an interaction term in the model. A priori, we considered P 
<0.10 suggestive of effect modification.
We assessed if the previously reported treatment-by-age effect 
modification3 was consistent by history of CHD, by adding a 3-way 
interaction term (treatment×age×history of CHD) to the model. We 
classified age into 3 groups (<70, 70–74, and ≥75 years) and assessed 
the change in procedural risk with increasing age stratified by treat-
ment and history of CHD. We used this classification of age because 
we sought to examine whether CAS is a safe alternative to CEA until 
a higher age in patients with history of CHD than the previously re-
ported cutoff of 70 years in the overall group.
Additional analyses for the primary outcome measure included an 
intention-to-treat (ITT) analysis including events that occurred within 
120 days after randomization in all patients who were randomized, 
irrespective of their compliance with the study protocol.
All analyses were done with R version 3.4.0.
Results
Of the 4754 patients, 113 (2%) patients had missing data on 
history of CHD and these patients were excluded from the 
analyses. Of the remaining 4641 patients, 1293 (28%) had his-
tory of CHD; this proportion varied across the 4 trials (range 
18%–38%; Table I in the online-only Data Supplement). 
Patients with history of CHD were more often male and more 
often had a history of hypertension, hyperlipidemia, diabetes 
mellitus, and peripheral artery disease than patients without 
history of CHD. Proportion of current smokers was higher in 
patients without history of CHD (Table 1).
Of the 4641 patients, 4486 remained for the PP analyses. 
In this group, stroke or death within 30 days after the pro-
cedure occurred in 251 (5.6%) patients (220 nonfatal strokes 
and 31 deaths). This risk was consistently higher in patients 
treated with CAS compared with CEA, both in patients with 
(8.3% CAS versus 4.6% CEA; HR, 1.96; 95% CI, 0.67–5.73) 
and in those without history of CHD (6.9% CAS versus 3.6% 
CEA; HR, 1.93; 95% CI, 1.40–2.65), and the CAS-to-CEA 
ratio was consistent between the subgroups (Pinteraction=0.89; 
Figure 1). Results were essentially the same for the ITT anal-
ysis of the primary outcome measure (Pinteraction=0.80; Figure I 
in the online-only Data Supplement). The results for the sec-
ondary outcome were virtually the same, with stroke, MI, or 
death within 30 days occurring in 128 (7.7%) patients after 
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CAS and in 78 (4.8%) patients after CEA from EVA-3S, 
SPACE, and ICSS. The CAS-to-CEA ratio was consistent be-
tween patients with and without history of CHD (HR, 1.44 
versus 1.74; Pinteraction=0.57; Figure II in the online-only Data 
Supplement).
Numbers and risks of stroke or death within 30 days of 
CAS and CEA, as well as CAS-to-CEA ratios for each age 
group, stratified by history of CHD, are provided in Table 2 
and Figure 2. In patients without history of CHD, the CAS-
to-CEA HR increased with advancing age, from equal risk 
for patients aged <70 years (HR, 1.05; 95% CI, 0.63–1.73) to 
increased risk for those aged 70 to 74 years (HR, 3.62; 95% CI, 
1.80–7.29) and for those aged ≥75 years (HR, 2.64; 95% CI, 
1.52–4.59). This increasing ratio was caused by an increasing 
event risk in CAS-treated patients, while risk was relatively 
stable in the CEA-treated patients across the age spectrum. 
The increasing risk after CAS was primarily driven by an 
increase in strokes, with a higher CAS-to-CEA HR across 
age strata (Table II in the online-only Data Supplement). In 
contrast, in patients with history of CHD, the CAS-to-CEA 
HR was equal in those aged <70 years (HR, 1.71; 95% CI, 
0.79–3.71) and those aged 70 to 74 years (HR, 1.09; 95% CI, 
0.45–2.65), whereas it was increased in those aged ≥75 years 
(HR, 2.78; 95% CI, 1.32–5.85). As previously reported, there 
was evidence of a treatment-by-age interaction for patients 
without history of CHD. Introduction of a 3-way interaction 
term (treatment×age×history of CHD) did suggest that the age 
modification of treatment effect was influenced by history of 
CHD status in the PP analysis (P=0.09).
Results were essentially similar for the ITT analysis of 
the primary outcome measure and the PP analysis of the sec-
ondary outcome measure, with the exception of the tests for 
a 3-way interaction (treatment×age×history of CHD) which 
were not statistically significant (P=0.25 and P=0.11; Figures 
III and IV in the online-only Data Supplement; Tables III and 
IV in the online-only Data Supplement).
Discussion
Our study showed that patients with symptomatic carotid 
stenosis and history of CHD had a higher procedural risk of 
stroke or death after CAS and CEA compared with patients 
without history of CHD, but CAS-to-CEA HRs were similar 
between the 2 groups. Therefore, CEA should not be avoided 
in patients with history of CHD. In patients with history of 
CHD, procedural stroke or death risk was almost equal after 
CAS and CEA for those younger than age 75 years, but 
higher after CAS relative to CEA for those aged 75 and older, 
whereas in patients without history of CHD, risk was only 
equal for those younger than age 70 years. However, because 
we did not find consistent evidence for modification of treat-
ment effect by age and history of CHD in both the PP and the 
ITT analyses and for both the primary and secondary outcome 
measures, these results must be interpreted with caution.
The previous pooled analysis of EVA-3S, SPACE, and 
ICSS showed a trend toward a lower CAS-to-CEA risk ratio 
in patients with history of CHD compared with patients 
without history of CHD (relative risk, 1.26 versus 1.66).5 With 
the addition of patients with symptomatic carotid stenosis 
enrolled in CREST, the HRs in the group with and without 
history of CHD became more similar (HR, 1.51 versus 1.61; 
Figure I in the online-only Data Supplement). Hence, our 
results did not confirm our hypothesis that CAS is as safe as 
CEA in patients with history of CHD. In CREST, the CAS-to-
CEA HR in patients with history of CHD was higher than in 
the other 3 trials (HR, 2.54; 95% CI, 1.11–5.80; Figure I in the 
online-only Data Supplement). This may be caused by differ-
ences in the study population characteristics of patients with 
history of CHD between the 4 trials because of differences in 
the definition of history of CHD. However, because the con-
fidence intervals of the CAS-to-CEA HRs in the 4 trials are 
wide and overlap, this may also be caused by chance alone.
The randomized SAPPHIRE trial (Stenting and 
Angioplasty With Protection in Patients at High Risk for 
Endarterectomy) investigated whether the presence of certain 
coexisting conditions that potentially increase the risk posed 
by CEA, among which clinically significant cardiac disease, 
influenced the safety of CAS compared with CEA. Stroke, 
MI, or death within 30 days after the procedure occurred in 
fewer patients who underwent CAS (4.8%) compared with 
those who underwent CEA (9.8%).11 These results are dif-
ferent from our results, which is most likely explained by 
differences between study populations: the SAPPHIRE trial 
included both patients with symptomatic and asymptomatic 
Table 1. Baseline Characteristics in Intention-to-Treat Population With and 
Without History of CHD
History of CHD
Yes (n=1293) No (n=3348)
Age at randomization in years, mean (SD) 70.6 (±8.7) 68.8 (±9.4)
Male sex 995 (77.0%) 2243 (67.0%)
History of
  Hypertension 1083 (83.8%) 2414 (72.1%)
  Hyperlipidemia* 1003 (77.6%) 1951 (58.3%)
  Diabetes mellitus 415 (32.1%) 754 (22.5%)
  Current smoking 241 (18.8%) 950 (28.4%)
  Stroke or TIA†‡ 192 (34.3%) 565 (34.0%)
  Peripheral artery disease‡ 126 (22.5%) 219 (13.2%)
Type of most recent ipsilateral ischemic event before randomization
  Retinal ischemia or amaurosis fugax 231 (18.0%) 574 (17.2%)
  TIA 521 (40.5%) 1168 (35.0%)
  Hemispheric stroke 534 (41.5%) 1592 (47.8%)
 Severe ipsilateral carotid artery 
stenosis (70%–99%)
1019 (78.8%) 2731 (81.6%)
 Contralateral severe carotid artery 
stenosis (≥70%) or occlusion
191 (16.2%) 431 (14.2%)
Data are presented as n (%), unless otherwise indicated. CHD indicates 
coronary heart disease; and TIA, transient ischemic attack.
*Defined as hyperlipidemia or taking lipid-lowering medication at 
randomization.
†Before the most recent ipsilateral ischemic event.
‡Data not collected in SPACE (Stent-Protected Angioplasty Versus Carotid 
Endarterectomy) and CREST (Carotid Revascularization Endarterectomy Versus 
Stenting Trial; 52% of patients).
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carotid stenosis, who were considered at high risk of com-
plications after CEA but of whom only a part (16.2%) had 
clinically significant CHD as coexisting condition. The trials 
contributing data to our pooled analysis enrolled symptomatic 
patients at standard surgical risk who were equally suited for 
both procedures.
Strokes contributed most to the composite primary and 
secondary outcome measure in our study, irrespective of 
history of CHD, whereas the absolute risk of MI was low. 
Indeed, CEA was associated with higher absolute risk of MI 
in patients with history of CHD versus those without history 
of CHD (0.7% versus 0.3%), whereas this was not the case for 
CAS (0.2% versus 0.2%), which is consistent with the find-
ings of a recent meta-analysis.4 However, the number of MIs 
was too small to examine effect modification by history of 
CHD for this outcome alone.
In 2 previous large cohort studies of patients who under-
went different types of noncardiac surgery (among which vas-
cular surgery) of whom some had history of CHD, the overall 
absolute risk of MI was much higher than in our study, 5.0% 
and 8.0%.12,13 In both studies, the risk of myocardial injury 
was higher in patients with than in those without history of 
CHD (5.9% versus 4.3% and 18.2% versus 6.6%).12,13 Only 
few studies have specifically compared the risk of MI after 
noncardiac surgery between patients with and without history 
of CHD. One study examined risk of MI in 377 CHD patients 
who underwent noncardiac vascular surgery and found an ab-
solute risk of MI of 26.5%.14 Several reasons may explain why 
the absolute risk of MI was lower in our study than in the 
aforementioned studies; no regular screening for procedural 
MI was performed in EVA-3S, SPACE, and ICSS, and eleva-
tion in cardiac enzymes without specific abnormalities on an 
ECG or typical chest discomfort was not counted as MI. Also, 
certain types of surgery other than carotid revascularization 
may involve more hemodynamic stress during the procedure 
and therefore may be associated with a higher risk of cardiac 
complications.
With regards to procedural stroke or death risk, our results 
suggest that CAS may be as safe as CEA in patients with 
history of CHD until the age of 75 years instead of the age 
of 70 years which is reported for the total group of patients 
with symptomatic carotid stenosis.3,15 One explanation for this 
Figure 1. Treatment hazard ratios (HRs) of stroke or death within 30 days after treatment according to history of coronary heart disease (CHD). Forest plots 
of carotid artery stenting (CAS) vs carotid endarterectomy (CEA) HRs in individual trials and in pooled analysis of patients with and without a history of CHD. 
Data are presented as n (%), unless otherwise indicated. Analysis was performed on a per-protocol basis. Interaction P value (stratified across trials): 0.89. 
CREST indicates Carotid Revascularization Endarterectomy Versus Stenting Trial; EVA-3S, Endarterectomy Versus Angioplasty in Patients With Symptomatic 
Severe Carotid Stenosis; ICSS, International Carotid Stenting Study; and SPACE, Stent-Protected Angioplasty Versus Carotid Endarterectomy.
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trend may be that patients who were assigned to CAS received 
more aggressive antiplatelet treatment than those assigned to 
CEA (mostly acetylsalicylic acid in combination with clopi-
dogrel), which may have prevented more procedural vascular 
events in patients with history of CHD who underwent CAS 
compared with those who underwent CEA. However, because 
the number of outcome events was low for patients with his-
tory of CHD in some age and treatment groups, and results 
were not consistent for both the primary and secondary out-
come measures, no definite conclusions can be drawn.
A strength of our study is that we pooled individual pa-
tient data from 4 randomized trials resulting in a large sample 
size. In addition, the proportion of patients with missing data 
on history of CHD was low (2%). Our study also has limi-
tations. First, the definition of history of CHD was not con-
sistent across all trials, which could have caused differences 
in treatment effect. However, we found little evidence of het-
erogeneity between trials in our analysis. Second, CREST 
patients could not be included in the analysis of the secondary 
outcome measure because the definition of MI in this trial 
was different from the definitions used in the other 3 trials. 
Consequently, the absolute number of clinical MIs was small. 
Third, we could not examine the treatment-by-age effect strat-
ified by history of CHD in more detail because we did not 
have sufficient power to classify patients with history of CHD 
into smaller age groups. Fourth, findings of our analysis rep-
resent results for CAS and CEA from about 10 to 15 years ago 
and may not represent that of a contemporary setting.
The current American Heart Association/American Stroke 
Association Guidelines for the Prevention of Stroke and 
Transient Ischemic Attack adopted the results of the previous 
pooled analysis on the age-treatment effect of CAS relative to 
CEA3 and suggested that CEA may give improved outcomes 
compared with CAS for patients aged 70 years or older.15 
Although our results suggest that CAS may be as safe as CEA 
up to the age of 75 years in patients with history of CHD, we 
did not find consistent statistical evidence for modification of 
treatment effect by age and history of CHD in both the PP and 
the ITT analyses and for both outcome measures. Therefore, 
further studies are needed to assess whether the treatment 
effect by age is truly different for patients with and without 
history of CHD.
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